Select a bar in the table to update this content
An unparalleled resource for the characterization of genes and their role in disease biology and drug response. Choose from thousands of cell lines available as part of our catalog.
The same team of cell line engineering scientists who developed our extensive cell line catalog are also available to generate cell lines on your behalf. Using our genome-editing platform, which comprises CRISPR, rAAV, and ZFN technologies, we are able to make almost any genetic alteration required, from simple knockouts or single point mutations to more complex genomic manipulations.
Horizon is your source for unique, next-generation SAGE® animal research models featuring specific gene deletions, insertions, repressions and modifications, as well as the industry's first and only knockout rat model.
Horizon has coupled our isogenic cell line library with our understanding of cancer biology and the tumor microenvironment along with a broad selection of libraries to be able to offer a range of screening approaches and assay conditions suitable to meet the requirements of almost any project.
Screening capabilities include:
Combination therapies are now emerging as the standard of care in indications such as cancer, inflammation, diabetes, and infectious disease. Horizon’s Combination High Throughput Screening platform (cHTS) operates by comparing a drug or other compound with a second at a specific dose to look for synergistic or antagonistic effects. These are seen by either increasing the anti-proliferative or cell killing effect.
Bioproduction cell lines should not be cost prohibitive. Horizon is revolutionizing the production of large molecule therapeutics, providing innovative solutions for all organizations of all sizes. We provide custom engineering of bioproduction cell lines and also offer a range of off the shelf CHO cell lines ready for immediate use.
Looking for a knockout rat or mouse not included in our standard model portfolio? Your Horizon in vivo model development specialist will work with you to design a custom model to your exact specifications, using our CRISPR-Cas9 or Zinc Finger Nuclease technologies, in as few as 5 months.
Neurological disease, defined as an abnormal function of the peripheral or central nervous system due to impaired electrical impulses throughout the brain or nervous system, is increasingly common, particularly given an aging population. In recent years, there has been growing evidence that genetics play a major role in many forms of neurological disease such as Alzheimer’s and Parkinson’s.
Major research efforts have helped us to understand the underlying pathology of many neurological disorders, with the hope of being able to introduce new diagnostic tools and to discover novel targets for new and more effective medications.
We are still in the early days of this research however. While population approaches have emerged as an indispensable component of genetic research in neurology, identifying many promising biomarkers of disease, much of the work to validate these markers, and to identify new ones, remains.
Horizon is uniquely suited to helping researchers investigate the underlying basis of disease. We translate genomic information into practical drug discovery and diagnostic tools that accurately recreate the specific genetics of real patients that are significant in human disease onset and progression.
Horizon’s gene editing platform confers the ability to rapidly introduce any genetic variation into any endogenous gene loci of any human cell line; thus accurately modeling real patient genotypes.
These disease models take the form of cell lines, which are being used widely in basic and drug discovery research and provide them as tools, use them as the basis of a wide range of services to power drug discovery and development programs, and offer them as reference standards to help ensure that patient diagnostic testing provides accurate results.
A particular strength to support neuroscience research is through Horizon’s in vivo models. We use our gene editing platform to generate these models, which are powerful tools used to investigate not only the impact of genetic modifications on the cognitive behavior of complex systems, but also to explore whether there are neurological side effects of therapeutics for drugs treating other conditions.
Dong M. et al. (2014). DAG1 mutations associated with asymptomatic hyperCKemia and hypoglycosylation of α-dystroglycan, Neurology. 2015 Jan 20;84(3):273-9
Kuldip D. et al. (2014). Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease, Neurobiology of Disease 70 (2014) 190–203
Shannon M. Hamilton, et al. (2014). Fmr1 and Nlgn3 Knockout Rats: Novel Tools for Investigating Autism Spectrum Disorders, Behavioral Neuroscience 2014, Vol. 128, No. 2, 103–109